J&J’s Janssen Pharmaceutical released new long-term data from the open-label period of the Phase III VOYAGE 1 study.
Following a disappointing review of interim data from a clinical study of GS-5745, an investigational anti-MMP9 antibody, Gilead said the company will halt the trial.
Takeda will refocus R&D on three targeted therapeutic areas – oncology, gastroenterology and CNS. Vaccines will also continue to play an important role.
April 20, 2016By Mark Terry, BioSpace.com Breaking News Staff South San Francisco-based Second Genome announced today that it had closed on a Series B investment round with $42.6 million. It was co-led by Pfizer Venture Investments and Roche Venture Fund. They were joined by new investors, Digitalis Ventures, Adveq, LifeForce Capital, MBL Venture Capital, […]
While Seres has seen explosive headcount growth over the past year, the company is planning for more. Seres is expanding its physical footprint in Cambridge and hiring more staff.
The patent for the ulcerative colitis drug LIALDA was upheld and extends through June 8, 2020.
Belgian biotech group Galapagos said its experimental drug to treat bowel disease ulcerative colitis had failed to prove its efficacy in a medical trial and it would discontinue the program for that disease. While the drug GLPG1205 was well tolerated, Galapagos said it did not perform better than the placebo given to another group of […]
– Strategic priorities include clinical-stage pipeline and core research function – SAN DIEGO, Oct. 27, 2015 /PRNewswire/ — Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) today announced plans to improve efficiencies and reduce costs as it focuses on the advancement of its research and development priorities. Arena intends to focus on its key strengths by concentrating […]
Nestle is working with Lipid Therapeutics to develop and commercialize a new therapeutic treatment for mild-to-moderate ulcerative colitis, which can causes ulcers, bleeding and pain due to inflammation of the colon, the company said on Wednesday. Nestle Health Science intends to develop an add-on therapy to an existing one that is commonly used but with […]
Biogen, Inc., headquartered in Cambridge, Mass., announced today that it licensed MT-1303 from Mitsubishi Tanabe Pharma Corporation, located in Osaka, Japan. MT-1303 is being investigated in a number of autoimmune disorders, including multiple sclerosis (MS), ulcerative colitis, Crohn’s disease and others. Biogen will obtain worldwide rights to MT-1303, excluding Asia. It will oversee global […]